48,460
edits
Difference between revisions of "Fibroblast growth factor receptors"
Jump to navigation
Jump to search
no edit summary
| Line 2: | Line 2: | ||
An anti-FGFR therapy exists (''erdafitinib'').<ref>{{cite journal |vauthors=Sheth H, Limaye S, Kumar P, Shreenivas A |title=Sustained response on sequential anti-FGFR therapy in metastatic gall bladder cancer: a case report and literature review |journal=J Cancer Res Clin Oncol |volume=149 |issue=8 |pages=4915–4923 |date=July 2023 |pmid=36307559 |doi=10.1007/s00432-022-04428-w |url=}}</ref><ref>{{cite journal |vauthors=Al-Obaidy KI, Cheng L |title=Fibroblast growth factor receptor (FGFR) gene: pathogenesis and treatment implications in urothelial carcinoma of the bladder |journal=J Clin Pathol |volume=74 |issue=8 |pages=491–495 |date=August 2021 |pmid=33731335 |doi=10.1136/jclinpath-2020-207115 |url=}}</ref> | An anti-FGFR therapy exists (''erdafitinib'').<ref>{{cite journal |vauthors=Sheth H, Limaye S, Kumar P, Shreenivas A |title=Sustained response on sequential anti-FGFR therapy in metastatic gall bladder cancer: a case report and literature review |journal=J Cancer Res Clin Oncol |volume=149 |issue=8 |pages=4915–4923 |date=July 2023 |pmid=36307559 |doi=10.1007/s00432-022-04428-w |url=}}</ref><ref>{{cite journal |vauthors=Al-Obaidy KI, Cheng L |title=Fibroblast growth factor receptor (FGFR) gene: pathogenesis and treatment implications in urothelial carcinoma of the bladder |journal=J Clin Pathol |volume=74 |issue=8 |pages=491–495 |date=August 2021 |pmid=33731335 |doi=10.1136/jclinpath-2020-207115 |url=}}</ref> | ||
==See also== | |||
*[[Classification of urothelial carcinoma by immunohistochemistry]]. | |||
==References== | ==References== | ||